Jump to: Authorized Access | Attribution | Authorized Requests

Study Description

We launched the IMPACT study to investigate the short- and long-term effects of SARS-CoV-2 vaccination on the immune system of patients with Multiple myeloma (MM) and its precursor conditions, Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM). We performed single-cell RNA-seq, coupled with single-cell T cell receptor (TCR) and B cell receptor (BCR)-sequencing on 224 samples, drawn pre- and post-vaccination from 114 individuals, including healthy donors, patients with MGUS, patients with SMM, and patients with overt MM.

Authorized Access
Publicly Available Data
  Link to other NCBI resources related to this study
Study Inclusion/Exclusion Criteria

Inclusion Criteria:

Participants who consent to participate in DFCI 14-174 (PCROWD) , DFCI 18-370 (PROMISE) , or DFCI 20-044 (CureCloud), regardless of race or sex.

Exclusion Criteria:

Individuals who have not consented to DFCI 14-174 (PCROWD), DFCI 18-370 (PROMISE) or DFCI 20-044 (CureCloud)

Selected Publications
Diseases/Traits Related to Study (MeSH terms)
Authorized Data Access Requests
Study Attribution
  • Principal Investigators
    • Irene M. Ghobrial, MD. Dana-Farber Cancer Institute, Boston, MA, USA.
  • Funding Source
    • R35CA263817-01A1. National Cancer Institute.